We are a group of motivated immunologists committed to delivering the power of cytokines to patients.
Founded in 2017 by leading experts in the field of immunotherapy, Anaveon is a biopharmaceutical company that specializes in the development of treatments for diseases with immune system dysfunction.
Our goal is to harness the power of engineered cytokines and develop novel treatments for diseases with high unmet need.
Years of Experience
Million CHF Funding
Anaveon doses first patient in a Phase I/II study to evaluate the safety, dosing and clinical activity of ANV419 in patients with solid tumors
Our dedicated team of experts has decades of experience in immunology, oncology and drug design. We use our deep knowledge to deliver novel drugs that address unmet medical needs.